Galecto Reports First Quarter 2025 Operating and Financial Results


BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.

View post:
Galecto Reports First Quarter 2025 Operating and Financial Results

Related Posts